Task F1 · contradiction handling
Is the finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected a settled consensus in the corpus, or is it contested/being re-evaluated?
Gold evidence
Acceptable answer concepts
- the abstract explicitly re-evaluates a prior study's finding
- framed as uncertain / under re-analysis, not settled consensus
- should not be reported as unqualified consensus
Construction note
PMID:42642214 opens by calling the prior result 'uncertain' and describes re-evaluating it on an independent cohort to reduce ascertainment/survivor bias -- a genuine in-corpus evidentiary tension, not a fabricated contradiction.
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 533 tokens · 3.4s(abstained) The provided query cannot be answered as no evidence passages were retrieved for this question.
The finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected is a settled consensus in the corpus.
The finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected is contested or being re-evaluated.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2816 tokens · 7.2sThe finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected is not a settled consensus but rather a finding supported by recent studies. The evidence suggests that the risk remains uncertain, with some studies indicating lower-than-expected incidence in the first decade following an ovarian cancer diagnosis.
Breast cancer risk after ovarian cancer in germline BRCA1/2 carriers remains uncertain.
A recent study reported lower-than-expected incidence of breast cancer in the first decade after ovarian cancer diagnosis in BRCA1/2 carriers.
The lower incidence of breast cancer after ovarian cancer is supported by the findings of a refined cohort study.
There is no agreement or consensus on this finding in the literature.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 3459 tokens · 8.3sThe finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected is not a settled consensus but rather a finding that remains uncertain and under re-evaluation.
Breast cancer risk after ovarian cancer in germline BRCA1/2 heterozygotes remains uncertain with recent studies reporting lower-than-expected incidence in the first decade.
Incidence of breast cancer after ovarian cancer was lowest within the first 5 years and increased beyond 10 years, aligning with findings from Apostol et al.
There is ongoing re-evaluation of breast cancer incidence after ovarian cancer in BRCA1/2 carriers.